Mar. 03 2023
Source Page: Non-technical summaries granted in 2021Found: CSF is obtained via a quick, minimally invasive surgical procedure under general anaesthetic so that
Increasing the access to minimally invasive cancer therapies is the last topic of today’s #LordsQs in a question from Lord Aberdare. 📺 Watch online from 3.05pm https://t.co/cszlVQNMfw 4/4 https://t.co/crJnX137d2
Jul. 27 2010
Source Page: Payment by results guidance for 2010-11. Incl. annexes and tables. 140 p.Found: Health technology assessment HTCS Healthcare travel cost scheme IAPT Improving access to psychological therapies
Jan. 31 2024
Source Page: Progressive Stroke Pathway remit and purpose: FOI releaseFound: INR: Interventional Neuroradiologist s: doctors who specialise in minimally invasive treatment of
Jul. 05 2023
Source Page: I. Letter dated 30/06/2023 from Steve Barclay MP to all MP The NHS Long Term Plan. 2p. II. NHS Long Term Workforce Plan. 151p.Found: moving planned care from overnight stays to day -case settings, with surgical techniques becoming less invasive
Jun. 30 2023
Source Page: What the NHS Long Term Workforce Plan means for youFound: moving planned care from overnight stays to day -case settings, with surgical techniques becoming less invasive
Asked by: Greg Smith (Conservative - Buckingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) clinical and (b) patient awareness of minimally invasive cancer therapies as outlined in the All-party parliamentary group on Minimally Invasive Cancer Therapies' recent report, Barriers to Patient Access.
Answered by James Morris
The All-Party Parliamentary Group’s report refers to a number of treatments which are not directly commissioned by NHS England and NHS Improvement. Where the National Institute for Health and Care Excellence has recommended a treatment following a technology appraisal, commissioners have a mandate to support implementation, including providing funding pathways where necessary.
For those treatments cited in the report which have received a positive technology appraisal, such as the use of selective internal radiation therapy (SIRT) to treat hepatocellular carcinoma, NHS England and NHS Improvement’s specialised commissioning team is currently expanding the number of providers. This involves a Prior Information Notice and market engagement exercise, which is due to be completed in 2022/23, before a service can be delegated to integrated care boards.
Asked by: Greg Smith (Conservative - Buckingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to take steps to implement the recommendations of the recently published report of the All-party parliamentary group on Minimally Invasive Cancer Therapies, Barriers to Patient Access; and if he will make a statement.
Answered by James Morris
The All-Party Parliamentary Group’s report refers to a number of treatments which are not directly commissioned by NHS England and NHS Improvement. Where the National Institute for Health and Care Excellence has recommended a treatment following a technology appraisal, commissioners have a mandate to support implementation, including providing funding pathways where necessary.
For those treatments cited in the report which have received a positive technology appraisal, such as the use of selective internal radiation therapy (SIRT) to treat hepatocellular carcinoma, NHS England and NHS Improvement’s specialised commissioning team is currently expanding the number of providers. This involves a Prior Information Notice and market engagement exercise, which is due to be completed in 2022/23, before a service can be delegated to integrated care boards.
Oct. 12 2022
Source Page: Private healthcare market investigationFound: Oncology The agreed maxima for the supervision of chemotherapy and other supportive therapies have
Oct. 12 2022
Source Page: Private healthcare market investigationFound: A2(1) -14 (d) a full cancer service including radiotherapy. 21 43.